More research is needed to further evaluate cost-effectiveness and efficacy of PPV strategies (single vs. multiple doses). However, weak evidence suggests that for patients aged 65-80 who have not received the PPV previously, a single-dose PPV strategy is both clinically and economically indicated. For patients 65 and above who have already received one dose of the PPV vaccine, the decision whether to revaccinate depends of vaccine tolerance and the cost-effectiveness/willingness-to-pay threshold used.
The information provided in this handout does not necessarily reflect the views of the University of Minnesota Medical School physicians and faculty. These materials are provided for informational purposes only and are in no way intended to take the place of the advice and recommendations of your personal health care provider. You use the information provided in these handouts at your own risk.
Pneumococcal Vaccination Guidelines.
Retrieved from the University of Minnesota Digital Conservancy,
Content distributed via the University of Minnesota's Digital Conservancy may be subject to additional license and use restrictions applied by the depositor.